The CDC has denied a request from California, Washington, Oregon, and Hawaii to validate a high-throughput measles diagnostic test, telling the West Coast Health Alliance it had "other competing priorities." The decision leaves U.S. public health laboratories without the ability to run batch measles testing on equipment they already own — machines purchased during the Covid pandemic specifically to handle outbreak-scale diagnostics. The gap is not theoretical. One measles patient can infect 12 to 18 unvaccinated people, and the virus lingers in the air for two hours. The post-exposure vaccine window is 72 hours. Speed of diagnosis directly determines whether an outbreak stays contained or goes exponential. Without validated high-throughput protocols, labs are stuck running individual PCR tests — a manual, lower-volume process that cannot keep pace with a fast-moving measles cluster. The infrastructure exists. During Covid, most public health labs acquired high-volume PCR platforms like the Hologic Panther Fusion, capable of processing 500 tests in eight hours. The problem is that no CDC-validated measles assay exists for these machines. ARUP Laboratories published their protocol in the Journal of Clinical Microbiology in December. Texas developed one during its west Texas outbreak last year but has not distributed it. The CDC reportedly studied both assays but conducted neither a full validation nor a comprehensive comparison. Validation matters because labs cannot simply improvise. Creating a diagnostic test from scratch requires planning, experimentation, documentation, and reliability verification — work that Benjamin Bradley, medical director of virology at ARUP, describes as "very burdensome" for individual labs. A CDC-validated and published protocol would let any qualified laboratory deploy the test immediately, rather than each lab reinventing the wheel. The HHS spokesperson's response is telling in what it avoids. Emily Hilliard said the CDC was "prioritizing emerging technologies" and "ensuring state and local health departments have the support needed." She did not answer whether the agency had any plans to validate a high-throughput measles test. The language of support without the substance of action. The West Coast Health Alliance's letter frames this as a preparedness issue extending beyond measles. A validated high-throughput protocol would establish the template for rapid diagnostic scaling against Ebola, hantavirus, and novel pathogens — the kind of infrastructure that either exists before an emergency or doesn't exist at all. The alliance is asking Schwartz to develop a measles assay for the Panther Fusion platform and publish it so any lab can deploy it. What makes this story structurally important is the specificity of the failure. This is not a resource question — the machines are in the labs, the assays have been developed, the journal papers are published. This is a validation bottleneck sitting inside a single federal agency that chose not to act, during an active and accelerating measles outbreak, while four states waited two months for an answer.
